Kura Oncology (NASDAQ:KURA) fell ~9% in regular trading on Thursday even as the cancer drug developer and its partner Kyowa Kirin (OTCPK:KYKOF) announced a mid-stage trial win for their jointly ...

AGEP can closely mimic generalized pustular psoriasis (GPP), requiring histopathologic confirmation and assessment of peripheral eosinophilia.

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

Eli Lilly plans to launch Mounjaro, an anti-diabetes and weight loss drug, in India by 2025. The medication, which is ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

Nigerian scientists have warned against the use of chemicals such as formalin, sodium benzoate in excessive amounts, and other unapproved preserva­tives, saying that the substances are unsafe and not ...

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with ...

The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...

FDA approves Journavx, a non-opioid medication for moderate to severe acute pain. Learn about its efficacy and side effects.